Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
When I started practicing law over 30 years ago — as hard as it is for many people to believe now — patent litigation was not “the thing” it is today. The U.S. Court of Appeals for the Federal Circuit, which is the court that hears all appeals in patent cases, was then only four years old. Patent “trolls,” as such, did not yet exist, although “submarine” patents did (Lemelson’s being the most well known). Some of the most famous patent owner friendly courts (e.g., the U.S. District Court for the Eastern District of Texas) had yet to emerge, and there were virtually no local patent rules. On the business side of the law, most firms in “Big Law” did not have a single patent attorney in the firm (and if they did, they had just one or two), and even those that did often did not handle patent cases. Thirty years later, this seems unthinkable.
Continue reading by getting
started with a subscription.
By Jonathan Moskin and Rachel Pauley
The emerging cases by authors and copyright owners challenging various generative AI programs for using copyrighted materials are certain to create new troubles for the courts being asked to apply the fair use doctrine to this important new technology.
By Jim Soong
Each decision involves reversal of a prior art rejection and contrasts with the other decisions on subject matter eligibility, revealing different PTAB approaches and results that can inform prosecution and appeal strategies.
By Leanne Rakers and Caley McCarthy
The future of antibody claiming in the United States is uncertain following the U.S. Supreme Court’s May 2023 ruling in Amgen Inc. v. Sanofi, a highly anticipated decision concerning enablement and whether the traditional way to claim antibodies — claiming antibodies by their function — will survive as a valid claiming strategy.
By Mark Liang, Paige Hardy and Grace McFee
Part Two of a Two-Part article
While the last decade has seen a dramatic increase in the number of AI patents, such patents face difficulty in overcoming the patent-eligibility challenges under §101 and Alice. Section 101, however, is not the only hurdles AI patents must overcome. Section 112, with its written description, enablement, and definiteness requirements, presents additional obstacles.